Expression of Bone Marrow Stromal Antigen 2 in Advanced Non-Small Cell Lung Cancer Tissues and Its Impact on the Prognosis of Cisplatin Chemotherapy
10.13241/j.cnki.pmb.2025.20.016
- VernacularTitle:骨髓基质细胞抗原2在中晚期非小细胞肺癌组织中的表达及对顺铂化疗预后的影响
- Author:
Xiang FU
1
;
Hao-qian XU
;
Ling-ping ZHU
;
Zhi-gang CHEN
;
Yuan-ya ZHANG
Author Information
1. 上饶市人民医院肿瘤科 江西上饶 334000
- Publication Type:Journal Article
- Keywords:
Bone marrow stromal antigen 2;
Non-small cell lung cancer;
Cisplatin;
Gemcitabine;
Chemotherapy;
Prognosis
- From:
Progress in Modern Biomedicine
2025;25(20):3322-3328
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the expression of bone marrow stromal antigen 2(BST2)in advanced non-small cell lung cancer(NSCLC)tissues and its impact on the prognosis of cisplatin chemotherapy.Methods:This study was a prospective study,127 advanced NSCLC patients who received treatment at Shangrao People's Hospital from January 2022 to December 2023 were prospective selected,all patients received cisplatin+gemcitabine chemotherapy regimen.They were divided into survival group(n=85)and death group(n=42)according to the prognosis.The relationship between expression of BST2 and clinicopathological characteristics was analyzed.The survival situation was analyzed by Kaplan-Meier method.Influencing factors of prognosis after cisplatin chemotherapy were discussed by univariate and multivariate COX regression analyses.Results:The positive expression rate of BST2 in cancer tissues(34.65％)in advanced NSCLC tissues was significantly higher than that in adjacent tissues(7.09％)(P＜0.05).Expression of BST2 was associated with tumor TNM staging,lymph node metastasis and differentiation degree(P＜0.05).The 1-year survival rate of patients with high expression of BST2(56.98％)was significantly lower than that of patients with low expression(87.80％)(P＜0.05).High expression of BST2 and TNM stage Ⅳ were independent prognostic risk factors for cisplatin chemotherapy in patients with advanced NSCLC(P＜0.05).Conclusion:The expressed of BST2 is highly in patients with advanced NSCLC tissues and closely related to cisplatin chemotherapy poor prognosis,suggesting its potential as a prognostic biomarker.
